These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25681528)

  • 1. Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
    Issy AC; Padovan-Neto FE; Lazzarini M; Bortolanza M; Del-Bel E
    Life Sci; 2015 Mar; 125():71-8. PubMed ID: 25681528
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA.
    Silva AS; Ariza D; Dias DP; Crestani CC; Martins-Pinge MC
    Life Sci; 2015 Apr; 127():82-9. PubMed ID: 25744393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
    Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
    Song L; Kong M; Ma Y; Ba M; Liu Z
    Brain Res; 2009 Jun; 1276():171-9. PubMed ID: 19393228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
    Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Inan SY; Soner BC; Sahin AS
    Metab Brain Dis; 2016 Aug; 31(4):849-57. PubMed ID: 26996632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
    Greenamyre JT
    J Neural Transm Gen Sect; 1993; 91(2-3):255-69. PubMed ID: 8099800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
    Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
    PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Useful data on parkinsonian syndromes].
    Espadaler Medina JM
    Med Clin (Barc); 1985 May; 84(20):828-33. PubMed ID: 4033265
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
    Lenda T; Ossowska K; Berghauzen-Maciejewska K; Matłoka M; Pieczykolan J; Wieczorek M; Konieczny J
    Eur J Pharmacol; 2021 Nov; 910():174460. PubMed ID: 34469756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.